OraSure Technologies, Inc. (NASDAQ:OSUR) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $15.46.

Several research firms have commented on OSUR. Jefferies Group LLC lifted their target price on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. BidaskClub cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Canaccord Genuity lifted their target price on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Stephens reaffirmed an “overweight” rating and issued a $19.00 target price (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Finally, Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Saturday, May 6th.

In related news, EVP Anthony Zezzo II sold 72,916 shares of OraSure Technologies stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the transaction, the executive vice president now owns 218,326 shares in the company, valued at approximately $4,641,610.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas A. Michels sold 290,495 shares of OraSure Technologies stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $16.75, for a total transaction of $4,865,791.25. Following the transaction, the chief executive officer now owns 894,012 shares in the company, valued at approximately $14,974,701. The disclosure for this sale can be found here. Insiders have sold a total of 1,036,670 shares of company stock valued at $19,807,152 over the last three months. Corporate insiders own 7.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. State Street Corp raised its position in OraSure Technologies by 6.3% in the fourth quarter. State Street Corp now owns 1,346,519 shares of the medical instruments supplier’s stock valued at $11,823,000 after buying an additional 79,922 shares during the last quarter. Norges Bank acquired a new position in OraSure Technologies during the fourth quarter valued at $9,786,000. Louisiana State Employees Retirement System acquired a new position in OraSure Technologies during the first quarter valued at $287,000. Nationwide Fund Advisors raised its position in OraSure Technologies by 209.1% in the first quarter. Nationwide Fund Advisors now owns 144,922 shares of the medical instruments supplier’s stock valued at $1,874,000 after buying an additional 98,034 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in OraSure Technologies by 48.6% in the first quarter. Fisher Asset Management LLC now owns 503,594 shares of the medical instruments supplier’s stock valued at $6,511,000 after buying an additional 164,630 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/11/orasure-technologies-inc-nasdaqosur-receives-consensus-rating-of-buy-from-brokerages.html.

Shares of OraSure Technologies (NASDAQ OSUR) traded up 2.12% on Friday, reaching $20.73. The company had a trading volume of 571,709 shares. OraSure Technologies has a 1-year low of $6.84 and a 1-year high of $21.59. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 38.32 and a beta of 1.57. The firm has a 50-day moving average price of $18.32 and a 200 day moving average price of $13.99.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million during the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. OraSure Technologies’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 EPS. Equities research analysts predict that OraSure Technologies will post $0.48 earnings per share for the current year.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.